Add to ORKGThere are currently no validated biomarkers predicting bevacizumab treatment outcome or toxicity. We combined biomarker data from six phase III trials of bevacizumab to assess whether genetic variation in vascular endothelial growth factor-A (VEGF-A) pathway or hypertension-related genes are associated with bevacizumab-induced hypertension.status: publishe
Purpose The most frequent bevacizumab-related side-effects are hypertension, proteinuria, bleeding a...
Background: In patients treated with bevacizumab, hypertension may be a biomarker of therapeutic eff...
Background: Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identifi...
There are currently no validated biomarkers predicting bevacizumab treatment outcome or toxicity. We...
Bevacizumab is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated as an ...
Background: Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No rel...
Despite extensive translational research, no validated biomarkers predictive of bevacizumab treatmen...
Insights into the molecular genetics of cancer have fueled the development of so-called targeted th...
Purpose: Bevacizumab is a VEGF-specific angiogenesis inhibitor indicated as an adjunct to chemothera...
Bevacizumab is a vascular endothelial growth factor-A-specific angiogenesis inhibitor indicated as a...
Purpose: Bevacizumab is a VEGF-specific angiogenesis inhibitor indicated as an adjunct to chemothera...
Studies assessing the effect of bevacizumab (BEV) on breast cancer (BC) outcome have shown different...
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that has antiangioge...
Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medic...
We previously reported improved pathologic complete response (pCR) in a prospective phase II study u...
Purpose The most frequent bevacizumab-related side-effects are hypertension, proteinuria, bleeding a...
Background: In patients treated with bevacizumab, hypertension may be a biomarker of therapeutic eff...
Background: Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identifi...
There are currently no validated biomarkers predicting bevacizumab treatment outcome or toxicity. We...
Bevacizumab is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated as an ...
Background: Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No rel...
Despite extensive translational research, no validated biomarkers predictive of bevacizumab treatmen...
Insights into the molecular genetics of cancer have fueled the development of so-called targeted th...
Purpose: Bevacizumab is a VEGF-specific angiogenesis inhibitor indicated as an adjunct to chemothera...
Bevacizumab is a vascular endothelial growth factor-A-specific angiogenesis inhibitor indicated as a...
Purpose: Bevacizumab is a VEGF-specific angiogenesis inhibitor indicated as an adjunct to chemothera...
Studies assessing the effect of bevacizumab (BEV) on breast cancer (BC) outcome have shown different...
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that has antiangioge...
Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medic...
We previously reported improved pathologic complete response (pCR) in a prospective phase II study u...
Purpose The most frequent bevacizumab-related side-effects are hypertension, proteinuria, bleeding a...
Background: In patients treated with bevacizumab, hypertension may be a biomarker of therapeutic eff...
Background: Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identifi...